Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

ets15,306228,505Total assets$

917,163$

1,244,533LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable, accrued liabilities and other current liabilities$

78,068$

92,097Deferred revenue86—Total current liabilities78,15492,097Convertible debt497,083497,083Other long-term liabilities19,74169,689Total liabilities594,978658,869Stockholders' equity:Common stock, $0.001 par value: 250,000,000 shares authorized at December 31, 2009 and September 30, 2010; 100,961,922 and 102,464,509 shares issued and outstanding at December 31, 2009 and September 30, 2010, respectively101103Additional paid-in capital899,950948,394Company common stock held by Nonqualified Deferred Compensation Plan(1,715)(2,176)Accumulated other comprehensive income (loss)933(1,581)Accumulated deficit(577,084)(359,076)Total stockholders' equity322,185585,664Total liabilities and stockholders' equity$

917,163$

1,244,533(1) December 31, 2009 balances were derived from the audited consolidated financial statements. BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONSFor the Three and Nine Months Ended September 30, 2009 and 2010(In thousands, except for per share data, unaudited)Three Months Ended September 30,Nine  Months Ended September 30,2009201020092010Revenues:Net product revenues$

78,383$

96,559$

231,769$

271,224Collaborative agreement revenues6481302,025507Royalty and license revenues1,7761,0613,7802,922Total revenues80,80797,750237,574274,653Operating expenses:Cost of sales (excludes amortization of developed product technology)14,97018,00349,18049,816Research and development26,99139,36687,673105,112Selling, general and administrative28,66738,34887,762109,625Intangible asset amortization and contingent consideration463,9722,9146,206Total operating expenses70,67499,689227,529270,759Income (loss) from operations10,133(1,939)10,0453,894Equity in the loss
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Host a Research and Development Day on October 19th
2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
6. BioMarin Acquires ZyStor Therapeutics, Inc.
7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
8. BioMarin to Acquire LEAD Therapeutics
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2009 Financial Results
11. BioMarin to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , Net Sales of $1.17 billion represent ... and an increase of 5.7% constant currency , Reported ... and adjusted earnings per share were $1.59, an increase of ... guidance Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2015.  The Company reported second quarter net sales ...
(Date:7/29/2015)... 30, 2015  Astellas today announced topline results ... efficacy and safety of intravenous (IV) and oral ... development for adults with candidemia and other invasive ... demonstrated that the trial did not meet its ... in isavuconazole-treated patients at the end of IV ...
(Date:7/29/2015)...  Nektar Therapeutics (Nasdaq: NKTR ) will announce its ... on Wednesday, August 5, 2015, after the close of U.S.-based ... officer, will host a conference call to review the results ... (PT). The press release and a live ... a link that is posted on the home page and ...
Breaking Medicine Technology:Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 2Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 3Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 4Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 5Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 6Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 7Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 8Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 9Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 10Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 11Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 12Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 13Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 14Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 15Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 16Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 17Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 18Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 19Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 20Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 21Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 22Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 23Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 24Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 25Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 26Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 27Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 28Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 29Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3
... PAREXEL International Corporation (NASDAQ: PRXL ), ... it will hold its annual seminar for biopharmaceutical companies ... on October 5, 2011 at the Grand Hyatt Tokyo ... for global drug development, as well as the implementation ...
... Pharmaceutical Company (the "Company") (NYSE:  KVa/KVb) today announced that ... Capital,s 5th Annual Global Opportunities Conference on Thursday, October ... Hyatt in New York. The presentation will ... go to the investor relations portion of the Company,s ...
Cached Medicine Technology:Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar 2Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar 3Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar 4
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students and ... Games, the largest sports and humanitarian event in the world this year and the ... Games, held July 25 through August 2, 2015, benefited from the participation of WesternU’s ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... On July ... $2 billion in taxpayer money to fund the state’s large prison system, which has ... with the highest rates of incarceration. In light of President Obama’s recent reduction of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to ... nonsurgical treatment designed specifically for the elimination of excess tissue under the chin, ... in the state of Wisconsin to offer this innovative treatment. , Developed by Kythera ...
(Date:7/30/2015)... Angeles, CA (PRWEB) , ... July 30, 2015 , ... ... gummy smiles, including lip lowering, gum contouring and surgery, as well as the patented ... technical artistry that has made him popular with many patients from around the world. ...
(Date:7/30/2015)... ... July 30, 2015 , ... The New Jersey Innovation Institute ... Department of Health, has received a $2.9 million grant from the Office of ... of Health and Human Services (HHS). NJII will help the Department of Health ...
Breaking Medicine News(10 mins):Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2
... ORANGE PARK, Fla., Feb. 19 Transitionz Wellness,Boutique ... child or adult, who,is a cancer survivor, is ... who is trying to get well, and we ... some of the best products and services,including wigs, ...
... (Feb. 19, 2008) -- A longstanding puzzle in neurodevelopment may ... by scientists at Weill Cornell Medical College says they have ... neuron,s long, skinny axon affect gene transcription back in the ... evidence of a transcription factor -- proteins that influence gene ...
... resolve issues, improve health, PITTSBURGH, Feb. 19 ... weeks for an appointment with an eye specialist ... edema and other vision,disorders. To address the urgency ... (POS) recently launched an initiative with,Highmark to offer ...
... Converge in Chicago, CHICAGO, Feb. 19 The ... Who: The Chicago Dental Society (CDS) recently polled ... dental habits, adults seeking,braces, and how the current presidential ... annual Midwinter Meeting, one of the largest,displays of dental ...
... LLC,today released notice of the final implementation schedule ... Part A and Part B,fee-for-service Medicare claims in ... reiterated the availability of its Jurisdiction 4 (J4),Web ... of the implementation,to health care providers in those ...
... essential for women who find menopause an intense and ... where health services are patchy or inaccessible. Thats the ... of the Journal of Advanced Nursing. , ... a predominantly rural Canadian province where a large proportion ...
Cached Medicine News:Health News:Transitionz Wellness Boutique Launches with Grand Opening Discounts 2Health News:Scientists shed light on long-distance signaling in developing neurons 2Health News:Scientists shed light on long-distance signaling in developing neurons 3Health News:Express Screening Process Aims to Put Diabetics on the Fast Track to Better Health 2Health News:Express Screening Process Aims to Put Diabetics on the Fast Track to Better Health 3Health News:TrailBlazer Announces Final Medicare Administrative Contractor Schedule for Claims Processing in Four States 2Health News:Menopausal women need better health care and community support in rural areas 2Health News:Menopausal women need better health care and community support in rural areas 3
... for rugged use; perfect tool with power ... helps reduce user fatigue. Internally lubricated for ... so that it will not break if ... extending blade life by 50% compared to ...
The True/Fix Cannulated Bone Screw System contains 7.0mm large cannulated bone screws and 3.5mm cortical and 4.0mm cannulated cancellous bone screws....
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
The Orengo staple is an oval staple, with thicker and longer legs (25 mm). It is then more especially bound to be used onto thick bones. The design of its stapler makes it more difficult to use und...
Medicine Products: